Peijia Medical (SEHK:9996) Stock Nears Breakeven As Revenue Momentum Builds

Peijia Medical stock closed at HK$4.98 on the day of its H1 2026 release after a choppy few months that left the 90 day return in decline. The market came in focused on whether the company could keep shrinking losses while still pushing top line growth in high end cardiovascular devices.

The headline is that Peijia Medical is selling more while bleeding far less. Revenue for H1 2026 reached ¥424.5m, while the net loss narrowed sharply to ¥7.6m. For long term investors in this still unprofitable stock, the story now shifts from survival risk to the pace of the march toward breakeven.

Is Peijia Medical now a genuine bargain after shrinking losses, or is the low share price simply reflecting ongoing risk? Compare your own view against the full valuation work in our valuation analysis for Peijia Medical

H1 2026 Earnings Summary

• Total Revenue (H1 2026 vs H1 2025): ¥424.5m vs. ¥353.4m (change of about 20%)
• Net Loss (H1 2026 vs H1 2025, excluding extra items): ¥7.6m loss vs. ¥69.9m loss (loss narrowed by about 89%)
• Basic EPS (H1 2026 vs H1 2025): ¥0.01 loss per share vs. ¥0.10 loss per share (loss per share fell by about 90%)
• Trailing Twelve Month Net Loss (TTM to H1 2026 vs TTM to H1 2025, excluding extra items): ¥141.0m loss vs. ¥225.2m loss (TTM loss narrowed by about 37%)

Prefer clean charts instead of scrolling through more tables and text on Peijia Medical? See the full visual picture of revenue trends and valuation progress in our company report for Peijia Medical.

Peijia Medical: Revenue Growth And Loss Compression Support Optimism

For bulls, Peijia Medical is starting to look more like a commercial story than a survival story. Revenue in H1 2026 reached ¥424.5m while the recurring net loss narrowed to ¥7.6m, with the trailing twelve month loss also shrinking. That points to improving operating leverage as the cardiovascular and neurovascular portfolio scales. The share price is still below its level 90 days ago, despite a stronger 30 day return, so the earnings trend and recent trading pattern together support a cautiously constructive view on the business direction.

Peijia Medical: Profitability Risks And Share Price Volatility Remain

The bearish side of the argument is not gone. Peijia Medical remains loss making on both a half year and trailing twelve month basis, which keeps execution and funding risk on the table. The stock declined about 6% over 90 days, even with a recent 30 day rebound, which suggests investors remain split on how sustainable these margin gains are in a competitive, capital hungry medical device sector. For now, the numbers ease near term worry, but they do not yet resolve longer term profitability questions.

With Peijia Medical still loss making and reliant on future execution, the real question is whether current cash, liabilities and cash burn can support this plan without painful funding moves. Check the full balance sheet and cash runway breakdown in our financial health analysis of Peijia Medical stock.

Take Control Of Your Next Move

If Peijia Medical's shrinking losses and growing revenue have your attention, register for free with Simply Wall St and add it to a Watchlist so you can track the share price against fair value and watch how the story develops. When you decide to build or adjust a position, keep a clear view of Peijia Medical alongside the rest of your holdings with the Portfolio Command Center that filters out noise and focuses on the updates that matter. For longer term conviction, tap into crowd wisdom and see how other investors are thinking about this stock through the Community. By spotting potential catalysts and risks early, you give yourself a better chance to act with confidence and stay ahead of the market.

Curious About Alternatives Beyond Peijia Medical

Fresh ideas move first. Stocks with real momentum often break out before the story is widely known. Look under the radar for now, before the crowd catches up, and consider acting while opportunities are still less widely followed.

• Spot resilient setups that may hold up when others wobble by scanning 295 resilient stocks with low risk scores and see which businesses keep their risk scores in check while interest is still building.
• Hunt for strong cash generators with sensible balance sheets by reviewing the curated list of solid balance sheet and fundamentals stocks (425 results) and see which companies could support growth plans without stretching finances.
• Explore potential upside from rising infrastructure momentum by screening 39 power grid technology and infrastructure stocks while the theme is still being priced in and before more investors react to earlier moves.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com